健民药业集团股份有限公司2025 年半年度报告 公司代码：600976 公司简称：健民集团 健民药业集团股份有限公司 2025 年半年度报告 1 / 152 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人汪俊、主管会计工作负责人程朝阳及会计机构负责人（会计主管人员）张英声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 健民药业集团股份有限公司2025 年半年度报告 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在 ...

北京商报讯（记者 丁宁）8月19日晚间，健民集团（600976）披露2025年半年报显示，公司上半年实现 的营业收入为18.05亿元，同比下降10.2%；归属净利润为2.21亿元，同比下降7.83%。 健民集团表示，本期营业收入同比下降10.2%，其中医药工业收入增长23.07%，医药商业收入下降 37.82%。医药商业收入下降主要是公司持续优化下属商业子公司业务结构，逐步收缩了部分低毛低效 的业务，导致医药商业板块业务收入有所下降，但公司医药商业板块加大创新性业务如医院SPD业务等 的拓展，业务结构得到持续优化。医药商业板块对公司利润贡献有限，收入的下降对利润的影响不大。 ...

Core Points - The company reported a decline in both operating revenue and net profit for the first half of 2025, with operating revenue at 1.805 billion yuan, a year-on-year decrease of 10.2%, and net profit at 221 million yuan, down 7.83% year-on-year [2] Summary by Category - **Financial Performance** - Operating revenue decreased to 1.805 billion yuan, representing a 10.2% decline compared to the previous year [2] - Net profit fell to 221 million yuan, reflecting a year-on-year decrease of 7.83% [2] - **Reasons for Decline** - The primary reasons for the decline in financial performance were reduced investment income from joint ventures and a decrease in non-recurring gains and losses [2]

Core Insights - The company reported a revenue of 1.805 billion yuan for the first half of 2025, representing a year-on-year decrease of 10.20% [1] - The net profit attributable to shareholders was 221 million yuan, down 7.83% year-on-year [1] - The net profit excluding non-recurring gains and losses was 195 million yuan, showing a year-on-year increase of 0.61% [1] - The basic earnings per share stood at 1.46 yuan [1]

Core Insights - The company reported a revenue of 1.805 billion yuan for the first half of 2025, representing a year-on-year decline of 10.20% [1] - The net profit for the same period was 221 million yuan, showing a year-on-year decrease of 7.83% [1] Financial Performance - Revenue: 1.805 billion yuan, down 10.20% year-on-year [1] - Net Profit: 221 million yuan, down 7.83% year-on-year [1]

Group 1 - The company has received the clinical trial approval notice for the nasal congestion granules from the National Medical Products Administration [1] - The nasal congestion granules are indicated for the treatment of acute sinusitis and have shown good efficacy and safety in clinical applications [1][2] - The market for nasal medication is significant, with 26% of the adult population in China suffering from nasal inflammation or sinusitis, and the market demand for nasal medication is expected to grow [2] Group 2 - The sales revenue for nasal medication (traditional Chinese medicine) is projected to be 2.757 billion yuan in 2023 and 3.061 billion yuan in 2024, with the nasal congestion granules expected to generate sales of 409 million yuan in 2023 and 475 million yuan in 2024 [2] - There are several traditional Chinese medicine products approved for the treatment of acute sinusitis, including nasal congestion granules, with one approval number for the nasal congestion granules [3] - The company must complete clinical trials and submit a marketing authorization application to the National Medical Products Administration before the product can be marketed [4]

Core Viewpoint - Jianmin Group has received the clinical trial approval notice for its nasal medication, indicating progress in its product development pipeline [2] Company Summary - Jianmin Group announced on August 14 that it has obtained the clinical trial approval from the National Medical Products Administration for its nasal medication, Nasal Congestion Relief Granules [2]

Group 1 - The core point of the article is that Jianmin Group has received the clinical trial approval notice for its nasal medication, indicating a significant development in its product pipeline [2] - Jianmin Group's revenue composition for the year 2024 is as follows: pharmaceutical manufacturing accounts for 49.83%, pharmaceutical commerce for 49.56%, and other businesses for 0.6% [2]

证券简称：健民集团 证券代码：600976 公告编号：2025-031 健民药业集团股份有限公司 关于获得《药物临床试验批准通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局签发的鼻渊通窍颗粒《药物临床试验批准通知书》。按照《上海证券交易所 上市公司自律监管指引第3号——行业信息披露》的相关要求，现将有关情况公告 如下： | 药品名称 | 鼻渊通窍颗粒 | 申请人 | 健民药业集团股份有限公司 | | --- | --- | --- | --- | | 注册分类 | 中药4类 | 剂型 | 颗粒剂 | | 通知书编号 | 2025LP02040 | 受理号 | CYZL2500001 | | 适应症 | 急性鼻窦炎 | | | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，鼻渊通窍颗粒临床试 | | | | | 验申请符合药品注册的有关要求，同意本品开展用于急性鼻窦炎的临床 | | | | | 试验。 | | | 二、药 ...

Core Viewpoint - Jianmin Group (600976.SH) has received the Clinical Trial Approval Notice for the nasal medication "Biyuan Tongqiao Granules" from the National Medical Products Administration, indicating a significant step in the development of this traditional Chinese medicine [1] Group 1 - The product "Biyuan Tongqiao Granules" is a traditional Chinese medicine that has already been marketed [1] - The primary function of the granules is to dispel wind and clear heat, as well as to promote lung function and open nasal passages [1] - The medication is indicated for acute nasal inflammation (acute sinusitis) associated with external pathogens affecting the lungs, with symptoms including pressure pain in the forehead or cheekbones, nasal congestion, and other related symptoms [1]